8-K Announcements
6Material company update
Feb 19, 2026·SEC
Material company update
Jan 30, 2026·SEC
Material company update
Dec 11, 2025·SEC
Madrigal Pharmaceuticals, Inc.(MDGL)Earnings, Financials & Key Ratios
MDGL•NASDAQ
$539.73
$12.25B mkt cap·Price updated May 6, 2026
AboutMadrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.Show more
- Revenue$958M+432.1%
- EBITDA-$300M+39.6%
- Net Income-$288M+38.1%
- EPS (Diluted)-12.85+41.3%
- Gross Margin94.14%-2.5%
- EBITDA Margin-31.31%+88.6%
- Operating Margin-31.31%+88.7%
- Net Margin-30.08%+88.4%
- ROE-42.49%+47.1%
- ROIC-38.18%+38.8%
- Debt/Equity0.00-98.9%
MDGL Key Insights
Madrigal Pharmaceuticals, Inc. (MDGL) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Negative free cash flow
- ✗Expensive at 20.1x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
MDGL Price & Volume
Madrigal Pharmaceuticals, Inc. (MDGL) stock price & volume — 10-year historical chart
Loading chart...
MDGL Growth Metrics
Madrigal Pharmaceuticals, Inc. (MDGL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM864.21%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM44.26%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM48.13%
Return on Capital
10 Years-66.26%
5 Years-89.36%
3 Years-67.77%
Last Year-32.94%
MDGL Recent Earnings
Madrigal Pharmaceuticals, Inc. (MDGL) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 4/12 qtrs (57%)
Q1 2026Latest
Feb 19, 2026EPS
$2.57
Est $0.04
-6525.0%
Revenue
$321M
Est $313M
+2.8%
Q4 2025
Nov 4, 2025EPS
$5.08
Est $2.04
-149.4%
Revenue
$287M
Est $245M
+17.3%
Q3 2025
Aug 5, 2025EPS
$1.90
Est $3.48
+45.4%
Revenue
$213M
Est $243M
-12.6%
Q2 2025
May 1, 2025EPS
$3.32
Est $3.62
+8.3%
Revenue
$137M
Est $159M
-13.6%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 19, 2026 | $2.57vs $0.04-6525.0% | $321Mvs $313M+2.8% |
| Q4 2025 | Nov 4, 2025 | $5.08vs $2.04-149.4% | $287Mvs $245M+17.3% |
| Q3 2025 | Aug 5, 2025 | $1.90vs $3.48+45.4% | $213Mvs $243M-12.6% |
| Q2 2025 | May 1, 2025 | $3.32vs $3.62+8.3% | $137Mvs $159M-13.6% |
Based on last 12 quarters of dataView full earnings history →
MDGL Peer Comparison
Madrigal Pharmaceuticals, Inc. (MDGL) competitors in Metabolic and Obesity Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 AKRO | 4.5B | 54.65 | -14.57 | -30.58% | 0.05 | |||
 HIMS | 6.8B | 26.33 | 51.63 | 59% | 5.47% | 23.73% | 1.09% | 2.07 |
 ELVN | 2.47B | 41.58 | -22.72 | -24.22% | ||||
 TERN | 4.64B | 52.97 | -47.29 | -29.95% | 0.00 | |||
 GPCR | 2.37B | 41.10 | -17.13 | -14.55% | 0.00 | |||
 NVCR | 1.81B | 15.88 | -13.02 | 8.28% | -25.66% | -50.82% | 0.85 | |
 HALO | 7.76B | 65.87 | 25.73 | 37.55% | 22.69% | 6.49% | 8.31% | |
 ARWR | 10.49B | 74.93 | -6141.80 | 232.58% | 18.54% | 35.64% | 1.5% | 0.73 |
Compare MDGL vs Peers
Madrigal Pharmaceuticals, Inc. (MDGL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MDGL Income Statement
Madrigal Pharmaceuticals, Inc. (MDGL) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 180.13M | 958.4M | 740.64M |
| Revenue Growth % | - | - | - | - | - | - | - | - | 432.05% | 864.21% |
| Cost of Goods Sold | 77K | 96K | 112K | 471K | 0 | 0 | 0 | 6.23M | 56.15M | 35.15M |
| COGS % of Revenue | - | - | - | - | - | - | - | 3.46% | 5.86% | - |
| Gross Profit | -77K▲ 0% | -96K▼ 24.7% | -112K▼ 16.7% | -471K▼ 320.5% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 173.9M▲ 0% | 902.25M▲ 418.8% | 705.5M▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | 96.54% | 94.14% | 95.25% |
| Gross Profit Growth % | -49258.97% | -24.68% | -16.67% | -320.54% | 100% | - | - | - | 418.84% | - |
| Operating Expenses | 31.81M | 40.36M | 94.86M | 205.85M | 242.48M | 293.57M | 380.5M | 671.77M | 1.2B | 1.01B |
| OpEx % of Revenue | - | - | - | - | - | - | - | 372.93% | 125.45% | - |
| Selling, General & Admin | 7.67M | 14.97M | 22.65M | 21.86M | 37.32M | 48.13M | 108.15M | 435.06M | 813.83M | 715.07M |
| SG&A % of Revenue | - | - | - | - | - | - | - | 241.52% | 84.91% | - |
| Research & Development | 24.39M | 25.39M | 72.32M | 184.81M | 205.16M | 245.44M | 272.35M | 236.72M | 388.52M | 297.9M |
| R&D % of Revenue | - | - | - | - | - | - | - | 131.41% | 40.54% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -31.89M▲ 0% | -40.46M▼ 26.9% | -94.97M▼ 134.8% | -206.32M▼ 117.2% | -242.48M▼ 17.5% | -293.57M▼ 21.1% | -380.5M▼ 29.6% | -497.88M▼ 30.8% | -300.1M▲ 39.7% | -307.48M▲ 0% |
| Operating Margin % | - | - | - | - | - | - | - | -276.39% | -31.31% | -41.52% |
| Operating Income Growth % | -27.64% | -26.88% | -134.75% | -117.24% | -17.53% | -21.07% | -29.61% | -30.85% | 39.72% | - |
| EBITDA | -31.81M | -40.36M | -94.86M | -205.85M | -242.08M | -293.1M | -379.97M | -496.78M | -300.1M | -306.01M |
| EBITDA Margin % | - | - | - | - | - | - | - | -275.78% | -31.31% | -41.32% |
| EBITDA Growth % | -27.33% | -26.88% | -135.03% | -117% | -17.6% | -21.08% | -29.64% | -30.74% | 39.59% | 44.08% |
| D&A (Non-Cash Add-back) | 77K | 96K | 112K | 471K | 405K | 467K | 527K | 1.1M | 0 | 1.48M |
| EBIT | -31.15M | -32.81M | -83.95M | -202.24M | -241.85M | -291.39M | -360.92M | -451.22M | 0 | -271.61M |
| Net Interest Income | 558K | 7.67M | 11.02M | 4.33M | 363K | -1.78M | 6.87M | 31.98M | 0 | 21.47M |
| Interest Income | 558K | 7.67M | 11.02M | 4.33M | 363K | 2.19M | 19.58M | 46.65M | 37.36M | 38.98M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 3.96M | 12.71M | 14.67M | -22.31M | 17.51M |
| Other Income/Expense | 732K | 7.64M | 11.02M | 4.08M | 636K | -1.78M | 6.87M | 31.98M | 11.81M | 18.36M |
| Pretax Income | -31.15M▲ 0% | -32.81M▼ 5.3% | -83.95M▼ 155.9% | -202.24M▼ 140.9% | -241.85M▼ 19.6% | -295.35M▼ 22.1% | -373.63M▼ 26.5% | -465.89M▼ 24.7% | -288.28M▲ 38.1% | -289.13M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - | - | -258.64% | -30.08% | -39.04% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -31.15M▲ 0% | -32.81M▼ 5.3% | -83.95M▼ 155.9% | -202.24M▼ 140.9% | -241.85M▼ 19.6% | -295.35M▼ 22.1% | -373.63M▼ 26.5% | -465.89M▼ 24.7% | -288.28M▲ 38.1% | -289.13M▲ 0% |
| Net Margin % | - | - | - | - | - | - | - | -258.64% | -30.08% | -39.04% |
| Net Income Growth % | -18.06% | -5.32% | -155.85% | -140.92% | -19.58% | -22.12% | -26.5% | -24.69% | 38.12% | 44.26% |
| Net Income (Continuing) | -31.15M | -32.81M | -83.95M | -202.24M | -241.85M | -295.35M | -373.63M | -465.89M | -288.28M | -289.13M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.54▲ 0% | -2.22▲ 12.6% | -4.73▼ 113.1% | -13.09▼ 176.7% | -14.63▼ 11.8% | -17.23▼ 17.8% | -19.99▼ 16.0% | -21.90▼ 9.6% | -12.85▲ 41.3% | -12.86▲ 0% |
| EPS Growth % | 49.9% | 12.6% | -113.06% | -176.74% | -11.76% | -17.77% | -16.02% | -9.55% | 41.32% | 48.13% |
| EPS (Basic) | -2.54 | -2.22 | -4.73 | -13.09 | -14.63 | -17.23 | -19.99 | -21.90 | -12.85 | - |
| Diluted Shares Outstanding | 12.24M | 14.8M | 15.39M | 15.45M | 16.54M | 17.14M | 18.69M | 21.27M | 22.43M | 22.48M |
| Basic Shares Outstanding | 12.24M | 14.8M | 15.39M | 15.45M | 16.54M | 17.14M | 18.69M | 21.27M | 22.43M | 22.48M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
MDGL Balance Sheet
Madrigal Pharmaceuticals, Inc. (MDGL) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 192.01M | 485.2M | 440.2M | 285.16M | 271.68M | 361.37M | 637.28M | 1.03B | 1.25B | 1.35B |
| Cash & Short-Term Investments | 191.53M | 483.72M | 439.05M | 284.15M | 270.35M | 358.77M | 634.13M | 926.25M | 983.56M | 1.11B |
| Cash Only | 148.63M | 57.38M | 46.7M | 54M | 36.27M | 331.55M | 99.92M | 100.02M | 198.69M | 295.69M |
| Short-Term Investments | 42.9M | 426.34M | 392.35M | 230.15M | 234.08M | 27.23M | 534.22M | 826.23M | 784.87M | 814.05M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 53.82M | 134.48M | 113.28M |
| Days Sales Outstanding | - | - | - | - | - | - | - | 109.06 | 51.21 | 37.92 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 34.07M | 74.84M | 69.32M |
| Days Inventory Outstanding | - | - | - | - | - | - | - | 1.99K | 486.52 | 576.72 |
| Other Current Assets | 485K | 1.48M | 1.15M | 0 | 0 | 2.6M | 3.15M | 18.79M | 52.89M | 5M |
| Total Non-Current Assets | 301K | 227K | 1.86M | 1.83M | 1.65M | 1.2M | 3.27M | 9.32M | 13.82M | 15.78M |
| Property, Plant & Equipment | 301K | 227K | 1.86M | 1.83M | 1.65M | 1.2M | 3.27M | 4.59M | 6.44M | 8.3M |
| Fixed Asset Turnover | - | - | - | - | - | - | - | 39.24x | 148.87x | 121.52x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.73M | 7.38M | 7.48M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 192.31M▲ 0% | 485.43M▲ 152.4% | 442.06M▼ 8.9% | 287M▼ 35.1% | 273.33M▼ 4.8% | 362.57M▲ 32.6% | 640.55M▲ 76.7% | 1.04B▲ 62.7% | 1.26B▲ 20.9% | 1.36B▲ 0% |
| Asset Turnover | - | - | - | - | - | - | - | 0.17x | 0.76x | 0.67x |
| Asset Growth % | 366.67% | 152.42% | -8.93% | -35.08% | -4.76% | 32.65% | 76.67% | 62.71% | 20.85% | 74.07% |
| Total Current Liabilities | 10.05M | 8.44M | 25.13M | 46.56M | 76.84M | 115.89M | 118.55M | 169.28M | 310.29M | 391.41M |
| Accounts Payable | 1.93M | 2.49M | 1.18M | 1.02M | 21.38M | 23.83M | 28.04M | 43.6M | 48.88M | 44.94M |
| Days Payables Outstanding | 9.14K | 9.46K | 3.84K | 788.12 | - | - | - | 2.55K | 317.74 | 437.68 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.02M | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 1.8M | 2.78M | 4.69M | 6.77M | 14.86M | 17.03M | 34.96M | 309.27M | 0 |
| Current Ratio | 19.10x | 57.46x | 17.52x | 6.13x | 3.54x | 3.12x | 5.38x | 6.10x | 4.01x | 4.01x |
| Quick Ratio | 19.10x | 57.46x | 17.52x | 6.13x | 3.54x | 3.12x | 5.38x | 5.90x | 3.77x | 3.77x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | -449.07 | 219.99 | 176.96 |
| Total Non-Current Liabilities | 0 | 0 | 361K | 468K | 387K | 49.29M | 116.67M | 118.59M | 36.32M | 345.32M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 49.29M | 115.48M | 117.57M | 0 | 339.75M |
| Capital Lease Obligations | 0 | 0 | 361K | 468K | 387K | 0 | 1.19M | 1.02M | 0 | 11.86M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 36.32M | 0 |
| Total Liabilities | 10.05M | 8.44M | 25.49M | 47.02M | 77.22M | 165.18M | 235.21M | 287.86M | 346.61M | 736.73M |
| Total Debt | 0 | 0 | 676K | 786K | 797K | 49.89M | 117.19M | 119.57M | 1.02M | 346.4M |
| Net Debt | -191.53M | -483.72M | -46.02M | -53.22M | -35.47M | -281.66M | 17.28M | 19.55M | -197.68M | 50.71M |
| Debt / Equity | - | - | 0.00x | 0.00x | 0.00x | 0.25x | 0.29x | 0.16x | 0.00x | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -1.13x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.17x |
| Interest Coverage | - | - | - | - | - | -74.06x | -29.93x | -33.94x | - | -15.51x |
| Total Equity | 182.26M▲ 0% | 476.98M▲ 161.7% | 416.56M▼ 12.7% | 239.97M▼ 42.4% | 196.11M▼ 18.3% | 197.39M▲ 0.7% | 405.33M▲ 105.3% | 754.38M▲ 86.1% | 602.69M▼ 20.1% | 625.73M▲ 0% |
| Equity Growth % | 400.57% | 161.71% | -12.67% | -42.39% | -18.28% | 0.65% | 105.35% | 86.11% | -20.11% | 31.36% |
| Book Value per Share | 14.88 | 32.24 | 27.06 | 15.54 | 11.86 | 11.52 | 21.69 | 35.46 | 26.86 | 27.83 |
| Total Shareholders' Equity | 182.26M | 476.98M | 416.56M | 239.97M | 196.11M | 197.39M | 405.33M | 754.38M | 602.69M | 625.73M |
| Common Stock | 1K | 2K | 2K | 2K | 2K | 2K | 2K | 2K | 2K | 2K |
| Retained Earnings | -106.46M | -139.27M | -223.22M | -425.46M | -667.31M | -962.66M | -1.34B | -1.8B | -2.09B | -2.03B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -31K | -319K | 216K | 47K | -80K | -32K | 468K | 468K | 873K | 1.07M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MDGL Cash Flow Statement
Madrigal Pharmaceuticals, Inc. (MDGL) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -22.32M | -25.51M | -41.62M | -157.56M | -183.92M | -224.86M | -324.23M | -455.57M | -189.55M | -189.55M |
| Operating CF Margin % | - | - | - | - | - | - | - | -252.91% | -19.78% | - |
| Operating CF Growth % | -26.75% | -14.29% | -63.19% | -278.53% | -16.73% | -22.26% | -44.19% | -40.51% | 58.39% | 294.03% |
| Net Income | -31.15M | -32.81M | -83.95M | -202.24M | -241.85M | -295.35M | -373.63M | -465.89M | -288.28M | -289.13M |
| Depreciation & Amortization | 77K | 96K | 112K | 471K | 405K | 467K | 527K | 696K | 4.72M | 3.36M |
| Stock-Based Compensation | 3.25M | 13.49M | 22.76M | 20.73M | 26.87M | 31.63M | 49.73M | 79.88M | 98.13M | 90.02M |
| Deferred Taxes | 0 | 0 | 0 | -21.83M | -7.32M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 2.49M | 13.12M | 0 | 21.83M | 7.32M | 797K | 2.41M | 2.09M | -4.12M | 4.85M |
| Working Capital Changes | 5.51M | -6.28M | 19.45M | 23.48M | 30.65M | 37.6M | -3.28M | -72.34M | 0 | 30.32M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -53.82M | -80.65M | -82.82M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -34.07M | -36.98M | -60.6M |
| Change in Payables | 917K | 558K | -1.31M | -161K | 20.36M | 2.45M | 4.21M | 15.56M | 5.28M | -2.03M |
| Cash from Investing | -22.01M | -380.08M | 30.71M | 159.78M | -5.05M | 206.69M | -502.52M | -274.39M | 32.32M | -43.21M |
| Capital Expenditures | -125K | -22K | -172K | -334K | -209K | -217K | -1.48M | -1.46M | -467K | -4.05M |
| CapEx % of Revenue | - | - | - | - | - | - | - | 0.81% | 0.05% | - |
| Acquisitions | 0 | -3.67M | 0 | 1.92M | 787K | -3K | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -21.88K | 3.67M | 0 | -1.92M | -787K | 3K | 0 | 19.09M | -8.97M | 0 |
| Cash from Financing | 173.81M | 314.33M | 235K | 5.09M | 171.24M | 313.45M | 595.12M | 735.06M | 255.98M | 266.8M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 50M | 65M | 0 | 0 | 218.91M |
| Equity Issued (Net) | 1000K | 1000K | 0 | 1000K | 1000K | 1000K | 1000K | 1000K | 0 | 2M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 2.51M | 235K | 667K | 1.03M | 8.07M | 269.93M | 337.57M | 255.98M | 10.38M |
| Net Change in Cash | 129.48M▲ 0% | -91.25M▼ 170.5% | -10.68M▲ 88.3% | 7.31M▲ 168.4% | -17.73M▼ 342.7% | 295.28M▲ 1765.0% | -231.63M▼ 178.4% | 5.1M▲ 102.2% | 98.76M▲ 1835.0% | 63.01M▲ 0% |
| Free Cash Flow | -22.44M▲ 0% | -25.53M▼ 13.8% | -41.8M▼ 63.7% | -157.9M▼ 277.8% | -184.13M▼ 16.6% | -225.07M▼ 22.2% | -325.71M▼ 44.7% | -457.03M▼ 40.3% | -190.02M▲ 58.4% | -161.63M▲ 0% |
| FCF Margin % | - | - | - | - | - | - | - | -253.72% | -19.83% | -21.82% |
| FCF Growth % | -27.43% | -13.76% | -63.72% | -277.78% | -16.61% | -22.24% | -44.71% | -40.32% | 58.42% | 63.13% |
| FCF per Share | -1.83 | -1.73 | -2.71 | -10.22 | -11.14 | -13.13 | -17.43 | -21.48 | -8.47 | -8.47 |
| FCF Conversion (FCF/Net Income) | 0.72x | 0.78x | 0.50x | 0.78x | 0.76x | 0.76x | 0.87x | 0.98x | 0.66x | 0.56x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MDGL Key Ratios
Madrigal Pharmaceuticals, Inc. (MDGL) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -28.49% | -9.95% | -18.79% | -61.61% | -110.92% | -150.12% | -123.98% | -80.35% | -42.49% | -46.21% |
| Return on Invested Capital (ROIC) | -161.9% | -13.39% | -18.03% | -55.53% | -104.7% | -576.64% | -168.69% | -62.41% | -38.18% | -38.18% |
| Gross Margin | - | - | - | - | - | - | - | 96.54% | 94.14% | 95.25% |
| Net Margin | - | - | - | - | - | - | - | -258.64% | -30.08% | -39.04% |
| Debt / Equity | - | - | 0.00x | 0.00x | 0.00x | 0.25x | 0.29x | 0.16x | 0.00x | 0.00x |
| Interest Coverage | - | - | - | - | - | -74.06x | -29.93x | -33.94x | - | -15.51x |
| FCF Conversion | 0.72x | 0.78x | 0.50x | 0.78x | 0.76x | 0.76x | 0.87x | 0.98x | 0.66x | 0.56x |
| Revenue Growth | - | - | - | - | - | - | - | - | 432.05% | 864.21% |
MDGL SEC Filings & Documents
Madrigal Pharmaceuticals, Inc. (MDGL) SEC filings — annual & quarterly reports (10-K, 10-Q)
MDGL Frequently Asked Questions
Madrigal Pharmaceuticals, Inc. (MDGL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Madrigal Pharmaceuticals, Inc. (MDGL) reported $740.6M in revenue for fiscal year 2025. This represents a 56698% increase from $1.3M in 2003.
Madrigal Pharmaceuticals, Inc. (MDGL) grew revenue by 432.1% over the past year. This is strong growth.
Madrigal Pharmaceuticals, Inc. (MDGL) reported a net loss of $289.1M for fiscal year 2025.
Dividend & Returns
Madrigal Pharmaceuticals, Inc. (MDGL) has a return on equity (ROE) of -42.5%. Negative ROE indicates the company is unprofitable.
Madrigal Pharmaceuticals, Inc. (MDGL) had negative free cash flow of $161.6M in fiscal year 2025, likely due to heavy capital investments.
Explore More MDGL
Madrigal Pharmaceuticals, Inc. (MDGL) financial analysis — history, returns, DCA and operating performance tools
Full MDGL Stock Analysis
Analyst verdict, bull/bear case, risk factors and peer comparison
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates